MYC and neoplasm: In patient samples, high AR activity was similarly required for anti-tumor activity of BAT, as there was no patient with a low ARAMW score (defined by our cut-off of less than 0.6) who exhibited significant downregulation of MYC and/or clinical evidence of tumor regression by BAT.